Next Article in Journal / Special Issue
The Neonatal Screening Program in Brazil, Focus on Sickle Cell Disease (SCD)
Previous Article in Journal
Building a Newborn Screening Information Management System from Theory to Practice
Previous Article in Special Issue
Newborn Screening for Sickle Cell Disease in the Caribbean: An Update of the Present Situation and of the Disease Prevalence
Article Menu

Export Article

Open AccessArticle
Int. J. Neonatal Screen. 2019, 5(1), 10; https://doi.org/10.3390/ijns5010010

A Multicentre Pilot Study of a Two-Tier Newborn Sickle Cell Disease Screening Procedure with a First Tier Based on a Fully Automated MALDI-TOF MS Platform

1
Biomaneo, 22B boulevard Winston Churchill, F-21000 Dijon, France
2
CLIPP, Clinical Innovation Proteomic Platform, Université de Bourgogne Franche Comté, F-21000 Dijon, France
3
Newborn Screening Laboratory, Biology and Pathology Center, Lille University Medical Centre, F-59000 Lille, France
*
Author to whom correspondence should be addressed.
Received: 4 December 2018 / Revised: 19 January 2019 / Accepted: 21 January 2019 / Published: 23 January 2019
  |  
PDF [1358 KB, uploaded 12 February 2019]
  |     |  

Abstract

The reference methods used for sickle cell disease (SCD) screening usually include two analytical steps: a first tier for differentiating haemoglobin S (HbS) heterozygotes, HbS homozygotes and β-thalassemia from other samples, and a confirmatory second tier. Here, we evaluated a first-tier approach based on a fully automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) platform with automated sample processing, a laboratory information management system and NeoSickle® software for automatic data interpretation. A total of 6701 samples (with high proportions of phenotypes homozygous (FS) or heterozygous (FAS) for the inherited genes for sickle haemoglobin and samples from premature newborns) were screened. The NeoSickle® software correctly classified 98.8% of the samples. This specific blood sample collection was enriched in qualified difficult samples (premature newborns, FAS samples, late and very late samples, etc.). In this study, the sensitivity of FS sample detection was found to be 100% on the Lille MS facility and 99% on the Dijon MS facility, and the specificity of FS sample detection was found to be 100% on both MS facilities. The MALDI-MS platform appears to be a robust solution for first-tier use to detect the HbS variant: it is reproducible and sensitive, it has the power to analyze 600–1000 samples per day and it can reduce the unit cost of testing thanks to maximal automation, minimal intervention by the medical team and good overall practicability. The MALDI-MS approach meets today’s criteria for the large-scale, cost-effective screening of newborns, children and adults. View Full-Text
Keywords: newborn screening; sickle cell disease; MALDI-TOF; mass spectrometry; thalassemia; prevention newborn screening; sickle cell disease; MALDI-TOF; mass spectrometry; thalassemia; prevention
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Naubourg, P.; El Osta, M.; Rageot, D.; Grunewald, O.; Renom, G.; Ducoroy, P.; Périni, J.-M. A Multicentre Pilot Study of a Two-Tier Newborn Sickle Cell Disease Screening Procedure with a First Tier Based on a Fully Automated MALDI-TOF MS Platform. Int. J. Neonatal Screen. 2019, 5, 10.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Neonatal Screen. EISSN 2409-515X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top